Global Stomach Cancer Treatment Market Size study & Forecast, by Type (Chemotherapy, Radiotherapy, Immunotherapy, Targeted Drug Therapy, Surgery), by End-users (Hospital Pharmacies, Specialty & Retail Pharmacies, Others) and Regional Analysis, 2022-2029

Global Stomach Cancer Treatment Market Size study & Forecast, by Type (Chemotherapy, Radiotherapy, Immunotherapy, Targeted Drug Therapy, Surgery), by End-users (Hospital Pharmacies, Specialty & Retail Pharmacies, Others) and Regional Analysis, 2022-2029

Global Stomach Cancer Treatment Market is valued at approximately USD 3.83 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 12.5% over the forecast period 2022-2029. Stomach cancer also commonly known as gastric cancer is characterized by the increasing number of cancerous cells within the lining of the stomach. According to the World Health Organization (WHO), stomach cancer accounts for the sixth most common type of cancer with a total of 1.09 million cases. Some of the risk factors related to stomach cancer are tumors, H. pylori bacterial infections, lymphoma, in other parts of the stomach polyps, and the digestive system. The increasing incidences of stomach or gastric cancer, rising expenditure on healthcare, coupled with the growing availability of skilled professionals and diagnostic tools for early detection of disease are the primary factors that are burgeoning the market demand around the world.

As per Globocan, in 2020, the prevalence of gastric cancer was nearly 1.1 million. Also, it is anticipated to reach 1.42 million by 2030. Likewise, according to the American Cancer Society, in 2022, there were nearly 26,380 new cases of stomach cancer (15,900 in men and 10,480 in women) and 11,090 deaths (6,690 men and 4,400 women) were recorded across the United States. Thereby, the rising incidences of stomach cancer are propelling the demand for stomach cancer treatment, which is augmenting the market growth across the globe. In addition, the growing availability of advanced healthcare facilities and the introduction of various novel therapies for metastatic stomach cancer are the factors that are creating various lucrative opportunities for global market growth in the forthcoming years. However, the lack of reimbursement for currently approved targeted therapies, along with the high cost of drugs and cancer treatment are hampering market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Stomach Cancer Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific dominated the space in terms of revenue, owing to the rising incidences of gastric cancer, high presence of target patient population, and growing investments in the development of advanced treatment options. Whereas, North America is expected to grow significantly during the forecast period Owing to factors such as presence of skilled professionals, availability of advanced healthcare facilities, and favorable government initiatives.

Major market players included in this report are:
Novartis AG
Pfizer, Inc.
Mylan N.V.
F. Hoffmann La Roche Ltd.
Eli Lilly And Company
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Celltrion Healthcare Co., Ltd.
Samsung Bioepis
Bristol Myers Squibb Company

Recent Developments in the Market:

In April 2021, Opdivo by Bristol-Myers Squibb in combination with fluoropyrimidine- and platinum-containing received the U.S. FDA approved chemotherapy for the treatment of metastatic gastric cancer.

In June 2021, Blueprint Medicines recently choose PANTHERx Rare Pharmacy and Biologics to distributes the company’s GIST treatment drug AYVAKIT. Based on the distribution channel.
Global Stomach Cancer Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage
Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered
Type, End-users, Region
Regional Scope
North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope
Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below.
By Type:
Chemotherapy
Radiotherapy
Immunotherapy
Targeted Drug Therapy
Surgery
By End-users:
Hospital Pharmacies
Specialty & Retail Pharmacies
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australi.
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Novartis AG
Pfizer, Inc.
Mylan N.V.
F. Hoffmann La Roche Ltd.
Eli Lilly And Company
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Celltrion Healthcare Co., Ltd.
Samsung Bioepis
Bristol Myers Squibb Company

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.